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1. Introduction 
Amyloidosis is a disease characterized by aberrant precursor molecules whose misfolded 
intermediate forms aggregate and are deposited as interstitial fibrils. The most common 
type of systemic amyloidosis is immunoglobulin light-chain amyloidosis (AL). Less 
common types of systemic amyloidosis are the transthyretin (ATTR) types caused by either 
mutant (hereditary) variants or wild-type ("senile systemic") transthyretin. Although rare in 
developed countries secondary amyloidosis is associated with autoimmune or inflammatory 
diseases, chronic infections and malignancies. Different precursor proteins can coexist in the 
same patient as in the African-American population, which has a 4% incidence of an hereditary 
ATTR variant (Val122Ile) and a significant incidence of monoclonal gammopathy (1, 2). 
The amyloids are highly ordered cross-ǃ sheet protein with extra cellular deposition in 
single or multiple organs. Cardiac deposition, leading to an infiltrative/restrictive 
cardiomyopathy, is a common feature and may be present at the diagnosis or discovered 
while investigating a patient presenting with non-cardiac amyloidosis. 
AL amyloidosis, is associated with clinical cardiac involvement in about half of all cases, 
although subclincal involvement may be detected in almost every case at autopsy on 
endomyocardial biopsy. Laser micro dissection with mass spectrometry assessing the 
constituents of the Congophilic deposits is now the gold standard for amyloid typing, 
obtaining protein type identification in over 98% of cases (3). 
Evaluation for cardiac involvement is a critical step of the initial staging of amyloidosis. 
Criteria for the assessment of organ involvement at baseline and after treatment have been 
standardized (4). In systemic AL amyloidosis the extent of cardiac involvement has 
prognostic indications, with a median survival of 6 months for untreated or non-responding 
patients (5, 6). 
2. Clotting alterations  
The cardiovascular complications observed in patients with amyloidosis range from 
myocardial involvement to haemostatic dysfunctions leading to thrombotic or hemorrhagic 
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complications. At presentation, 15-40% of patients with AL amyloidosis experience 
hemorrhagic manifestations (7, 8). Petecchiae, purpura in periorbital and facial areas 
ecchymosis and bleeding tendencies are common clinical features and severe hemorrhages 
may contribute to worsening the clinical course and lead to death. Increased fragility of 
blood vessels and impaired vasoconstriction, caused by deposition of insoluble fiber, are 
frequent causes of bleeding (9, 10). Acquired coagulation factor deficiency, most commonly 
factor X, is a unique feature of AL amyloidosis. In a reported large series of patients with 
primary amyloidosis, 8.9% showed factor X deficiency (defined as factor X activity < 50%); 
about half of them experienced bleeding episodes and the severity and frequency of these 
episodes was most pronounced with the lowest factor X levels(11). Absorption of the 
coagulation factor by AL fibrils, primarily in the liver and spleen is the proposed 
pathogenetic mechanism. Deficiency of factor X in patients with splenic amyloid in some 
cases has been corrected by splenectomy wich can produce resolution of the bleeding 
diathesis (12). Normalization of factor X levels has been reported after oral melphalan 
chemotherapy. Resolution of the bleeding episode was also described in five of 10 patients 
treated with high dose melphalan followed by autologous stem cell transplantation 
although bleeding complications in the peritransplant period were fatal in two patients (13). 
Perivascular amyloid deposition, inhibition of fibrinogen conversion to fibrin, and specific 
deficiencies of factor X, IX, and V along with circulating heparin-like anticoagulants play 
important roles in determing the haemostatic abnormalities. 
Prolongation of pro-thrombin time (PT), thrombin time (TT), reptilase time (RT) and 
Russell’s viper venom time (RVVT) are the most common coagulation abnormalities. 
Abnormal fibrinogen and/or elevated fibrinogen/fibrin degradation products (FDP) are 
considered to be the main factors that affect both TT and RT. It has been postulated that 
inhibitors must be present in plasma of patients with AL amyloidosis and the inhibitory 
activity persists in the supernatant even after fibrinogen precipitation (14). Several 
pathologic conditions other than the presence of a plasma thrombin inhibitor could explain 
the prolongation of aPTT and PT in AL patients e.g. malabsorption associated with amyloid 
deposits in the gastrointestinal tract, reduced food intake due to macroglossia or vomiting, 
liver failure and plasma deficiencies of some clotting factors due to their affinity for amyloid 
deposits. 
Although TT and RT prolongations are peculiar features of AL Amyloidosis, they do not 
predict bleeding manifestations. Other coagulation abnormalities such as factor X 
deficiency, enhanced fibrinolysis, and amyloid angiopathy seem to correlate better with 
clinical symptoms (15). 
Deficiencies in specific coagulation factors in have long been recognized and along with 
factor X, acquired deficiencies in factor IX, factor II and factor VII have also been described 
(16). Hypofibrinogenemia has also been observed in systemic AL amyloidosis in association 
with disseminated intravascular coagulation and increased fibrinolysis (17). 
Hyperfibrinolysis related to a reduced level of ǂ2-antiplasmin or to a complex formed with 
plasmin can be associated with either bleeding manifestations or abnormal coagulation tests 
in patients with amyloidosis. Bleeding diathesis associated with a shortened clot lysis time 
and elevated FDP is pathognomonic. The pathogenesis appears to be related to a reduced 
level of ǂ2-antiplasmin, often secondary to complex formation with plasmin (18, 19). 
Increased urokinase plasminogen activator activity also has been observed a patient with 
primary amyloidosis. Immunoprecipitation studies showed that single-chain urokinase 
plasminogen activator was the main fibrinolytic agonist in the patient's plasma. Treatment 
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with ε-amino-caproic acid was effective in controlling bleeding symptoms in some patients, 
even when accelerated fibrinolysis is not demonstrable (20). Standard chemotherapy and 
new novel agents can also induce bleeding complications by multiple mechanisms. Drugs 
with anti-angiogenic activity may be associated with vascular complications in amyloidosis 
patients and their use should be closely monitored as these patients could have pre-existing 
haemostatic abnormalities associated with their paraproteins. 
3. Cardiac amyloidosis  
Definition of cardiac involvement (cardiomegaly, pleural effusions, and Kerley B lines on 
the chest radiograph) (21) over the past three decades has been supplanted by 
echocardiography. A granular sparkling appearance with wall thickening, diastolic 
relaxation abnormalities, right ventricular dysfunction and abnormal echocardiography 
strain have all been shown to be associated with prognosis (22). Serum cardiac biomarkers 
have been recently introduced and serum troponin T and N-terminal pro-brain natriuretic 
peptide (NT-proBNP) are now widely available. Using a cutoff value of 0.035 mcg/L 
Troponin T and 332 pg/mL NT-proBNP, patients can be classified into three stages: Stage I 
both biomarkers low (33% incidence); Stage II, only 1 marker high (37% ); Stage III both 
values high (30% incidence) . The reported median survivals are 26.4, 10 and 3.5 months, 
respectively for Stages I, II, III (23). 
The cardiac biomarkers values have been validated in different cohorts of patients treated 
with either conventional chemotherapy or stem cell transplantation (SCT) (24). Stage III 
patients are at high mortality risk in SCT studies and also are poor candidates for clinical 
trials of standard agents (25). 
Echocardiography is one of the earliest tests employed in the investigation of suspected 
heart disease. The specificity of the echocardiographyc findings increases in the presence of 
the clinical manifestations suggestive of myocardial amyloidosis. The earliest finding in 
cardiac amyloidosis is suggested by reduced diastolic mitral inflow velocities upon Doppler 
imaging (26, 27). 
A granular sparkling texture of the myocardium with increased thickness is strongly 
suggestive of cardiac amyloid infiltration with a specificity approaching 81%. The addition 
of the finding of increased septal diameter remarkably increases the specificity of ventricular 
wall thickness parameter; an interventricular septum thickness of more than 15 mm is also 
considered a poor prognostic sign (28).The thickness of the left ventricular walls correlates 
with reduced survival. Low voltage/mass ratio strongly favors the diagnosis of amyloid 
myocardial infiltration (29). Typical clinical presentation of cardiac amyloidosis with specific 
echocardiographyc findings such as dilated atria, interatrial septal hypertrophy > 7 mm, 
thickened valves and right ventricular free wall has been proposed as diagnostic of cardiac 
amyloidosis even without an endomyocardial biopsy (30). 
The diagnosis can be confirmed by endomyocardial biopsy and the extent of involvement 
appears as the most important determinant of clinical outcome as cardiac troponin and NT-
proBNP have been shown to be potent prognostic indicators, the suppression of 
amyloidogenic serum light chains by treatment and reductions in NT-proBNP have been 
associated with improved outcome. 
Circulating amyloidogenic light chains interact with cardiac cell membrane constituents and 
other local matrix components. Extracellular space amyloid deposition causes myocardial 
damage by direct cell toxicity mediated by the formation of light chain oligomers (31). The 
www.intechopen.com
 
Amyloidosis – An Insight to Disease of Systems and Novel Therapies 
 
56 
pathologic features are thickening of all four chambers, biatrial dilatation, a normal or 
mildly dilated right ventricle and a left ventricular cavity that is normal or small. 
Myocardial cells are separated and distorted by amyloid deposition. Intramyocardial vessels 
are frequently infiltrated by amyloid, resulting in impaired vasodilatation, which may result 
in myocardial ischemia. Rarely amyloid deposits have been found in epicardial vessels 
resulting in obstructive coronary artery disease indistinguishable on coronary angiography 
from cholesterol-laden plaques. The predominant manifestation of amyloid heart disease is 
congestive failure (32). 
Accumulation of amyloid in the myocardial interstitium results in late gadolinium 
enhancement, often with a predominant diffuse, global and subendocardial distribution that 
matches the distribution of amyloid on histology although other more focal patterns have 
also been reported. This is associated with substantial alteration in gadolinium kinetics, with 
faster washout of gadolinium from blood and myocardium than normal (33). Some studies 
have suggested that gadolinium kinetics may be even more predictive than 
echocardiography or serum markers. The value of the Cardiovascular Magnetic Resonance 
(CMR) measurements may in part be due to the fact that cardiac amyloid burden cannot be 
measured satisfactorily by other techniques, and therefore CMR may offer a fundamental 
new window into the cardiac pathology in this disease (34). Recognition that T1 mapping in 
cardiac amyloidosis may be significantly more predictive of poor prognosis than the other 
currently used measures ,its use may be justified when early and more intensive 
chemotherapy is planned . 
A number of the gadolinium kinetics parameters have been significantly associated with 
mortality, but the one with greatest discriminatory value was the intra-myocardial T1 
gradient after gadolinium injection, with 95% accuracy at a threshold value of 23 ms (Kaplan 
Meier analysis P = 0.002). Although further experience and reproduction of these results by 
other centers is necessary, the technique is in principle straightforward and could be 
implemented on most 1.5T scanners (35). 
4. Gene expression and cytogenetic abnormalities 
Gene expression profiling studies have revealed subsets of genes associated with the 
development of amyloidosis. A unique molecular profile for AL amyloidosis may be 
relevant to the development of disease.  
The comparison of gene expression profiles between AL, normal BM and myeloma plasma 
cells has revealed that AL plasma cells had an intermediate transcription profile. A few 
genes may be of particular relevance in understanding the differences in the pathobiology of 
these two disease entities. One of these, TNFRSF7, a member of the tumor necrosis factor 
(TNR) receptor superfamily which codes for CD27, a marker expressed on memory B cells 
and is important in controlling maturation and apoptosis of plasma cells, has a higher average 
expression in AL plasma cells. CD27 has been postulated to be important in the oncogenesis 
of myeloma, since MM plasma cells (PC) do not express this marker, whereas normal PCs 
do, and the expression of CD27 declines with the more advanced stages of MM. CD27 interacts 
with its ligand CD70, and this interaction is thought to be important in the differentiation of 
plasma cells. Interestingly, the tail of CD27 binds a proapoptotic protein, Siva, and CD27-70 
interaction may activate a death signal that determines the life span of PCs. 
CD27 expression is progressively down regulated in the transition from normal plasma cells 
to MGUS to MM to myeloma cell lines suggesting that molecular mechanism in AL disease 
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is an early event. Another gene that was significantly different between AL and MM was the 
chemokine SDF-1, which is comparatively more highly expressed in AL PCs. However, 
SDF-1 levels in normal PCs are higher than those expressed in AL (36, 37). Whereas over 
expression of SDF-1 has been implicated in preventing apoptosis, promoting proliferation 
and metastatic spread in a number of neoplastic diseases through interactions with CXCR4, 
it is apparent that the relatively high levels of SDF-1 in normal and AL PCs have a 
paradoxical effect. This paradox can be explained by the binding of SDF-1 to CXCR4 which 
results in activation of the suppressors of cytokine signaling (SOCS) proteins, in particular, 
SOCS-3, which can negatively regulate CXCR4 function without interfering with surface 
receptor expression. 
Clonal AL plasma cells express recurring cytogenetic abnormalities, including t(11,14), gain 
11q, del 13q, and gain 1q.Interestingly, t(11;14) was associated with worse overall survival in 
a recent study of AL patients (38). Over expression of cyclin D1 (CCND1 located on 
chromosome 11q13) in purified AL plasma cells occurs in one-half of AL patients and is 
associated with unique pathobiologic characteristics at diagnosis: including high frequencies 
of light-chain only M proteins and kappa light chains, increased cardiac biomarker levels, 
and poorer overall survival (39). 
5. Therapy  
The therapy aim for AL amyloidosis is to eliminate the clonal plasma cells producing the 
toxic precursor protein. Once a case of amyloidosis is recognized, it is vital to precisely 
determine the type of amyloid as the prognosis and treatment differ considerably among the 
various types. The management of heart failure in patients with amyloidosis remains 
challenging. Judicious diuretics use and salt restriction with avoidance of intravascular 
volume depletion remains the mainstay of the treatment. Angiotensin-converting enzyme 
inhibitors and Angiotensin-II receptor blockers are poorly tolerated in cardiac amyloidosis. 
The role of calcium channel blockers and digoxin is limited and probably detrimental. This 
is due to an exaggerated negative inotropic effect. A high incidence of sudden death in 
patients treated with digoxin has been reported (40). 
Heart transplantation remains a controversial option because of the systemic involvement 
and the potential recurrence of graft Amyloidosis (41). In primary amyloidosis, heart 
transplantation is only a palliative procedure and consequent supportive chemotherapy 
should be considered. The long-term prognosis is poor (39% survival at 4 years in one study 
and 30% at 5 years in another, even with adjuvant chemotherapy. Sequential heart and 
autologous stem cell transplantation for primary amyloidosis has been reported (42). 
Active agents in the treatment of the amyloid include corticosteroids (prednisone, 
dexamethasone), alkylating agents (melphalan, cyclophosphamide), immunomodulatory 
drugs (thalidomide, lenalidomide) and proteasome inhibitors (bortezomib).Conventional 
chemotherapy based on melphalan and prednisone was introduced in 1972 can achieve a 
median survival of 12 to 18 months and in patients with severe cardiac failure, continuous, 
oral, daily melphalan has been used as palliative method (43). Based on the observation that 
dexamethasone as single agent was able to produce hematological and organ responses, 
melphalan and dexamethasone have been later used in combination in this setting (44). 
Melphalan and dexamethasone is still now considered a front-line therapy, inducing a 
hematological response of 67% of the time with a 33% of CR and an organ response rate of 
48% in a phase II study of 45 patients. A 5-year follow-up the study showed a median PFS of 
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3.8 years and OS of 5.1 years. Subsequent studies have later confirmed the efficacy of this 
combination (45). 
Amyloid therapy remained unchanged until the introduction of stem cell transplantation 
(SCT) wich was designed to target rapidly the amyloidogenic light chain production by the 
clonal plasma cell populations. High rates of hematological and organ response have now 
been documented in multiple centers with long-term data reported and median survivals of 
over a decade for SCT patients achieving complete response. The high rate of treatment-
related mortality (5 to 10% even at experienced centers) would explain the failure to show a 
survival advantage when compared to standard therapy in a large prospective randomized 
trial (46). Risk-adapted SCT, which tailors the melphalan dose according to age and risk 
status of the patient, may improve early survival (47). To compensate for the loss of efficacy 
due to attenuated conditioning, adjuvant therapy post SCT for patients not achieving a CR 
has been tested. Thalidomide and dexamethasone or bortezomib and dexamethasone has 
been used as adjuvant therapy post SCT with CR rates at 12 months post SCT of 39% and 
65% of evaluated patients (48). 
The propensity for sudden cardiac death, the frequency of multi-organ involvement and the 
problem of progressive organ disease and drug-related side effects has limited clinical 
research in amyloid. The first novel agent to be tested in relapsed AL was thalidomide. 
Initially it was poorly tolerated at high doses but showed efficacy at moderate doses in 
combination with dexamethasone and alkylating agents (melphalan or cyclophosphamide) 
resulting in hematological and organ responses. Current reccomendations suggest to start 
with thalidomide at a dose of 50 mg daily and it can be increased if tolerated (49). 
Lenalidomide has been combined with dexamethasone in two studies with hematological 
response of 41% and 67% respectively. Several phase I/II combining Lenalidomide and 
dexamethasone with an alkylating agent (melphalan or cyclophosphamide) have been 
recently completed. In a phase 1/2 dose-escalation study of lenalidomide in combination 
with melphalan and dexamethasone. A complete hematological response was achieved in 
42% at the dose of 15 mg of lenalidomide per day. After a median follow-up of 19 months, 
estimated 2-year overall survival (OS) and event-free survival (EFS) were 80.8% and 53.8% 
respectively (50). 
In a preliminary report on a phase II study of the thalidomide derivative pomalidomide 
with weekly dexamethasone in AL amyloidosis patients previously treated with SCT and 
alkylating agents lenalinamide or thalidomide one-third achieved a hematological response 
by 6 months, highlighting the promising anti amyloid effect of this potent 
immunomodulatory drug (51). 
Bortezomib is a selective inhibitor of the 26S proteasome, a protein complex involved in the 
regulation of degradation of aberrant proteins as well as for the regulation of other proteins 
involved in the regulation of apoptosis, and cell-cycle progression.  
Single agent Bortezomib in a phase I dose escalation study achieved hematological 
responses in 50% of patients and CR in 20%. A multicenter study of 94 AL amyloid patients 
treated with bortezomib with or without dexamethasone has reported hematological 
responses in 71% and CR in 25% of patients; cardiac response was documented in 29% of 
subjects (52). Bortezomib is currently being evaluated in combination with melphalan and 
dexamethasone in 2 trials in Europe and USA. 
The past decade has seen significant advances in the treatment of patients with AL, leading 
to improvement s in both quality of life and survival. The novel agents have significantly 
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expanded the armamentarium against AL. The central challenges of this decade will be how 
to combine these agents and how to bring forth new ones for approval. 
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